biotech · Post Traumatic Stress Disorder · Prosthetic Joint Infection · ADPT
Adaptive Biotechnologies Corp
Adaptive Biotechnologies drug portfolio — 23 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 23 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Adaptive Biotechnologies drug portfolio — 23 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L03) compound in Adaptive Biotechnologies's portfolio. Mechanism: Somatic cell supplemental therapy.
Development asset linked to Adaptive Biotechnologies in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
Development asset linked to Adaptive Biotechnologies in public FDA and regional records.
Nervous system (N05) compound in Adaptive Biotechnologies's portfolio. Molecular target: Orexin receptor.
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
Antiinfectives for systemic use (J07) compound in Adaptive Biotechnologies's portfolio.
Development asset linked to Adaptive Biotechnologies in public FDA and regional records.
Development asset linked to Adaptive Biotechnologies in public FDA and regional records.
Antineoplastic and immunomodulating agents (L01) compound in Adaptive Biotechnologies's portfolio. Molecular target: B-lymphocyte antigen CD20.
US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
US regulatory status: approved. Molecular target: Programmed cell death protein 1.
US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
Development asset linked to Adaptive Biotechnologies in public FDA and regional records.
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
US regulatory status: approved.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
Development asset linked to Adaptive Biotechnologies in public FDA and regional records.
Nervous system (N07) compound in Adaptive Biotechnologies's portfolio.
US regulatory status: approved. Molecular target: Apoptosis regulator Bcl-2.
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 1A.